Does Retatrutide Cause Hair Loss? A Look at the Phase 2 Data and the Mechanism

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited · Author: FormBlends Editorial

Key Takeaways

• Retatrutide is investigational and not FDA-approved. FormBlends does not sell, supply, or formulate retatrutide. This page is educational.
• Phase 2 retatrutide data reported alopecia at rates higher than placebo. The pattern matches telogen effluvium driven by rapid weight loss, not a drug-specific follicle effect.
• The same hair shedding occurs with semaglutide and tirzepatide. Phase 2 retatrutide rates appear similar or somewhat higher, likely because of larger total weight loss.
• Hair shedding typically starts 2-4 months after starting therapy or after substantial weight loss begins, and resolves within 6-12 months once weight stabilizes.
• Prevention strategies include adequate protein (1.2-1.6 g/kg/day), iron and ferritin monitoring, B12 and vitamin D supplementation if low, and slower titration. These reduce but do not eliminate the risk.

Direct answer

Yes, retatrutide can cause hair loss. The phase 2 obesity trial (Jastreboff et al., NEJM June 2023) reported alopecia at rates higher than placebo, with frequencies that scaled roughly with dose. The pattern matches telogen effluvium, the diffuse shedding triggered by rapid weight loss rather than a direct follicle effect of the drug itself. The condition is typically reversible once weight stabilizes. The same hair loss pattern occurs with semaglutide and tirzepatide; the retatrutide rates appear similar to or somewhat higher than its predecessors, likely reflecting the larger magnitude of weight loss.

Table of contents

1. What the phase 2 data actually showed
2. The mechanism: telogen effluvium, not direct follicle damage
3. Comparison: retatrutide vs semaglutide vs tirzepatide hair loss rates
4. The weight loss rate hypothesis
5. Who is most likely to experience hair loss on retatrutide
6. What hair shedding looks like vs other hair loss patterns
7. The timeline of telogen effluvium
8. Prevention strategies that have evidence
9. Treatment options when shedding has started
10. When to see a dermatologist
11. The contrary view: should hair loss be a deal-breaker
12. FAQ
13. Sources

What the phase 2 data actually showed

The phase 2 retatrutide obesity trial (Jastreboff AM et al., NEJM June 2023, N=338, 48 weeks) included alopecia as a reported adverse event. Approximate rates by dose group:

Dose arm	Alopecia incidence at 48 weeks
Placebo	~1%
Retatrutide 1 mg	~3%
Retatrutide 4 mg	~7%
Retatrutide 8 mg	~13%
Retatrutide 12 mg	~16%

Two patterns stand out. First, the rate increases with dose, which would be expected if hair loss correlates with magnitude of weight loss. Second, even the highest reported rate (16%) means most participants did not experience hair shedding significant enough to be reported.

The phase 2 publication did not characterize severity in detail. Most reported alopecia in incretin trials is mild to moderate diffuse shedding rather than dramatic patchy loss. Severe alopecia leading to treatment discontinuation was uncommon.

The mechanism: telogen effluvium, not direct follicle damage

Understanding the hair loss mechanism matters because it determines whether the loss is reversible and how to prevent or treat it.

Human hair follicles cycle through three phases:

• Anagen (growth): The active growth phase, lasting 2-7 years. Most hair on the scalp is in anagen at any given time.
• Catagen (transition): A brief 2-3 week transitional phase.
• Telogen (rest): A resting phase lasting about 3 months, after which the hair sheds.

Under normal conditions, about 85-90% of scalp hairs are in anagen and about 10-15% are in telogen, with shedding around 50-150 hairs per day.

Telogen effluvium occurs when a physiological stressor causes a synchronized shift of many follicles from anagen to telogen. About 2-4 months later, those follicles shed their hairs together, producing diffuse shedding that the person perceives as "I'm losing my hair."

Common telogen effluvium triggers include:

• Rapid weight loss (any cause: dieting, surgery, medication)
• Major surgery
• Significant illness or fever
• Childbirth (postpartum telogen effluvium)
• Severe psychological stress
• Major nutritional deficiency (iron, B12, protein, zinc)
• Thyroid dysfunction

Retatrutide-associated alopecia maps onto the rapid weight loss trigger. The drug itself is not directly toxic to hair follicles. The weight loss it produces is what triggers the synchronized telogen shift.

This mechanism distinction matters: telogen effluvium is generally reversible. Once the trigger stabilizes (weight stops dropping rapidly, nutritional intake is adequate), the follicles resume normal cycling and the hair density typically returns within 6-12 months.

Comparison: retatrutide vs semaglutide vs tirzepatide hair loss rates

Drug	Trial	Alopecia rate (max dose)	Placebo rate	Mean weight loss
Semaglutide 2.4 mg	STEP 1	~3%	~1%	~14.9%
Tirzepatide 15 mg	SURMOUNT-1	~4-6%	~1%	~22.5%
Retatrutide 12 mg	Phase 2 (Jastreboff 2023)	~16%	~1%	~24.2%

The pattern: alopecia rates rise with weight loss magnitude. This is consistent with telogen effluvium driven by rapid weight loss rather than a drug-specific effect.

A caveat: trial-reported alopecia depends on how participants and investigators define and document the symptom. Different trials may have used different thresholds for reporting. Cross-trial comparison of adverse event rates is approximate, not precise. The general pattern (more weight loss, more hair loss) is robust, but the exact numerical comparisons should not be over-interpreted.

The weight loss rate hypothesis

If telogen effluvium is driven by rapid weight loss, then slowing the rate of weight loss should reduce hair shedding. Several lines of evidence support this:

• Surgical weight loss (very rapid) is associated with high rates of telogen effluvium, typically 30-50%
• Severe caloric restriction diets are associated with hair shedding at rates comparable to surgery
• Gradual weight loss through moderate dieting is associated with lower rates
• Pharmacologic weight loss produces hair shedding at rates roughly proportional to the speed of weight loss

Implications for retatrutide:

• Slower titration may reduce hair loss incidence. Achieving the same total weight loss over a longer period reduces the synchronization of follicle cycling.
• Lower maintenance doses (8 mg instead of 12 mg) may produce slightly less hair loss along with slightly less weight loss.
• The cumulative duration of active weight loss matters more than the duration of drug exposure. A patient who reaches a stable weight and remains there is less likely to continue experiencing shedding.

Who is most likely to experience hair loss on retatrutide

Although individual variation is wide, several patient features appear associated with higher telogen effluvium risk:

• Women. Postpartum telogen effluvium reveals a female susceptibility to this mechanism, partly hormonal. Women appear to report alopecia at higher rates than men in incretin trials.
• Pre-existing low iron or ferritin. Iron deficiency is a major contributor to telogen effluvium. Patients starting with low ferritin (especially below 30 ng/mL) are more likely to experience shedding.
• Concurrent androgenetic alopecia. Patients with male or female pattern hair loss may experience apparent worsening because telogen effluvium adds diffuse shedding on top of pattern thinning.
• Inadequate protein intake. Many patients on incretin therapy reduce overall food intake but maintain a low-protein dietary pattern. Protein deficiency contributes to follicle dysfunction.
• Thyroid dysfunction. Hypothyroidism causes hair shedding independently and may be unmasked or worsened during rapid metabolic change.
• Faster weight loss trajectory. Patients who tolerate aggressive titration and lose weight rapidly are more likely to experience shedding than those with gradual loss.
• Age and baseline hair density. Older patients with already-thinning hair may notice shedding more dramatically than younger patients with denser baseline.

What hair shedding looks like vs other hair loss patterns

Telogen effluvium has a distinctive pattern that helps distinguish it from other forms of hair loss:

Feature	Telogen effluvium	Androgenetic alopecia	Alopecia areata	Anagen effluvium
Distribution	Diffuse, all over scalp	Pattern (crown, vertex, temples)	Discrete patches	Diffuse
Onset	Sudden, 2-4 months after trigger	Gradual over years	Sudden patches	Days to weeks after trigger
Cause	Physiological stressor	Genetic, hormonal	Autoimmune	Chemotherapy, radiation, severe toxins
Hair pull test	Positive (more than 3 hairs)	Negative or weakly positive	Positive at patch margins	Strongly positive
Reversibility	Usually fully reversible	Progressive without treatment	Sometimes reversible	Reversible after trigger removed

Retatrutide-associated alopecia is typically telogen effluvium. Patients describe noticing more hair in the shower, on the pillow, or in the hairbrush. The hair part may appear wider. The overall scalp coverage may seem thinner. Patchy bald spots or rapid total hair loss is not characteristic.

If hair loss is patchy, very rapid, or includes other unusual features (scalp pain, scaling, breakage of hair shafts), evaluation by a dermatologist is appropriate to rule out other causes.

The timeline of telogen effluvium

The typical timeline for telogen effluvium triggered by weight loss:

• Month 0: Start of weight loss trigger (initiation of medication or onset of rapid loss)
• Month 1-2: Follicles synchronize toward telogen phase, but visible shedding has not started yet
• Month 2-4: Shedding begins, often noticed in the shower or on bedding. Hair density may visibly thin.
• Month 4-6: Peak shedding. This is often when patients seek evaluation.
• Month 6-9: Shedding rate decreases as new anagen hairs begin growing.
• Month 9-12: Hair density typically returns to or near baseline.

For retatrutide specifically, this timeline applies to patients who reach maintenance weight by months 6-9. Patients who continue losing weight beyond that point may experience more prolonged shedding because the trigger continues. Patients who plateau and remain stable typically see resolution within 6-12 months of plateau.

Prevention strategies that have evidence

Several strategies have supporting evidence for reducing telogen effluvium during rapid weight loss:

Adequate protein intake. Target 1.2-1.6 g/kg body weight per day during active weight loss. Higher than the standard 0.8 g/kg recommendation, lower than the elite athlete range. Protein is structurally essential for hair follicle function and is often underconsumed on incretin therapy due to appetite suppression.

Iron and ferritin optimization. Baseline labs before significant weight loss. Address iron deficiency before it contributes to alopecia. Target ferritin >40-50 ng/mL specifically for hair health, although the optimal range is debated.

Vitamin D. Low vitamin D is associated with various forms of hair loss. Supplementation if below 30 ng/mL.

B vitamins. Biotin specifically has weak evidence except in documented deficiency, but a B-complex supplement is reasonable for patients with reduced food intake.

Zinc. Often included in hair-specific supplements. Evidence is modest, but zinc deficiency does contribute to alopecia.

Slower titration. Allowing more time at each dose level reduces the rate of weight loss and may reduce telogen synchronization. The trade-off is longer time to reach maintenance dose.

Thyroid screening. Baseline TSH, with retesting if shedding begins. Hypothyroidism can be unmasked during metabolic stress.

Realistic expectation setting. Knowing that hair shedding can occur, what it looks like, and that it typically resolves reduces psychological distress and helps patients distinguish telogen effluvium from more concerning conditions.

Treatment options when shedding has started

Once telogen effluvium is established, the primary "treatment" is removing or stabilizing the trigger. For weight loss-induced shedding, this means achieving weight stability. Additional measures:

• Continued nutritional optimization. The strategies above remain relevant during active shedding.
• Topical minoxidil. Modest evidence for accelerating recovery in telogen effluvium. Available over the counter at 5% strength.
• Gentle hair care. Avoiding aggressive styling, harsh chemicals, or tight hairstyles during active shedding reduces breakage and helps preserve apparent density.
• Reassurance. Most cases resolve. Counting hairs lost in the shower amplifies anxiety without changing the trajectory.
• Dermatology evaluation. Appropriate if shedding is severe, prolonged beyond 12 months, or accompanied by other unusual features.

Hair growth supplements marketed as "anti-shedding" formulas have weak evidence. Most provide standard nutrients (biotin, iron, zinc, vitamin D) at modest doses. They are not harmful but are unlikely to outperform addressing actual deficiencies with targeted supplementation.

When to see a dermatologist

For most retatrutide-associated alopecia, primary care or the prescribing clinician can manage the situation. Dermatology evaluation is appropriate when:

• Hair loss is patchy rather than diffuse
• Shedding persists more than 12 months after weight stabilizes
• Scalp symptoms (pain, scaling, redness) accompany the shedding
• Hair breaks rather than sheds (suggests anagen effluvium or trichorrhexis)
• Pattern hair loss (crown, vertex, temples) progresses despite weight stabilization
• Eyebrow, eyelash, or body hair loss accompanies scalp shedding
• The pattern of loss is concerning to the patient or clinician

A dermatologist can perform a hair pull test, examine the scalp under magnification (trichoscopy), order targeted labs, and rule out alopecia areata, frontal fibrosing alopecia, lichen planopilaris, or other conditions that require specific treatment.

The contrary view: should hair loss be a deal-breaker

For some patients, the prospect of hair shedding is enough to refuse incretin therapy. The argument deserves respect.

Argument for considering it serious: Hair density is a meaningful part of self-image and identity. Visible shedding during a period when other body changes are also happening can compound psychological distress. The shedding can be persistent enough to be visible in photos and to other people.

Argument for context: The 16% rate at the highest retatrutide dose is meaningful but means 84% of participants did not report meaningful alopecia. Most cases are mild and reversible. The trade-off between hair shedding and the metabolic benefits of significant weight loss favors continuing therapy for most patients with obesity-related health risks.

Argument from base rates: Pattern hair loss affects roughly 50% of men and 25% of women by age 50, regardless of weight loss medication. Distinguishing medication-attributable shedding from age-related thinning can be difficult. The drug may receive blame for changes that would have occurred anyway.

The honest synthesis: Hair loss is a real risk on retatrutide, more prominent than with other approved obesity drugs because the weight loss is larger. For most patients, it is temporary and manageable. For patients whose primary motivation is appearance and who are at low metabolic health risk, the trade-off may not favor therapy. For patients with significant obesity-related comorbidities, the health benefits typically outweigh the cosmetic costs.

FAQ

Does retatrutide cause hair loss? Yes, in some patients. Phase 2 reported alopecia at rates higher than placebo, scaling with dose.

How common is hair loss on retatrutide? At the highest phase 2 dose (12 mg), about 16% of participants reported alopecia. Lower doses had lower rates.

Is the hair loss permanent? Generally no. Telogen effluvium from weight loss typically resolves within 6-12 months after weight stabilizes.

Why does retatrutide cause hair loss? The mechanism is telogen effluvium driven by rapid weight loss, not a direct follicle effect. The same pattern occurs with any rapid weight loss.

When does the hair loss start? Typically 2-4 months after starting therapy or after substantial weight loss begins.

Can I prevent hair loss on retatrutide? Prevention strategies include adequate protein (1.2-1.6 g/kg/day), iron and ferritin monitoring, vitamin D supplementation if low, slower titration, and thyroid screening. These reduce but do not eliminate risk.

Should I take biotin? Biotin alone has weak evidence except in documented deficiency. A general B-complex is reasonable. Hair-specific supplements rarely outperform addressing specific deficiencies.

Does hair grow back after stopping retatrutide? Hair density typically returns to baseline once weight stabilizes, whether or not the medication is continued. Stopping the drug is not necessary for hair recovery in most cases.

Is retatrutide hair loss worse than other GLP-1 drugs? Phase 2 rates appear similar to or somewhat higher than semaglutide and tirzepatide, consistent with the larger weight loss retatrutide produces.

Do all GLP-1 drugs cause hair loss? All incretin drugs that produce significant weight loss can trigger telogen effluvium. The rate correlates with weight loss magnitude, not with the specific drug.

Should I stop retatrutide if my hair is shedding? Decisions about therapy should involve the prescribing clinician. For most patients, telogen effluvium does not warrant stopping. Slower titration, nutritional optimization, and time typically resolve the issue.

Can I take a hair growth supplement while on retatrutide? Standard hair supplements are generally safe with incretin therapy. They may help if deficiencies are present. They rarely provide dramatic benefit beyond what targeted supplementation accomplishes.

Related guides

• Does Retatrutide Cause Hair Loss?
• Does Retatrutide Cause Muscle Loss? Lean Mass Data and What to Do About It
• What Does Retatrutide Do? A Direct Look at the Phase 2 Numbers
• Does Retatrutide Cause Diarrhea? The Phase 2 Numbers in Context
• Is Retatrutide Safe? An Honest Read of the Phase 2 Data
• Retatrutide and Hair Loss: What to Expect and How to Manage

Sources

1. Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. June 2023.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
4. Malkud S. Telogen Effluvium: A Review. Journal of Clinical and Diagnostic Research. 2015.
5. Hughes EC, Saleh D. Telogen Effluvium. StatPearls. Updated 2024.
6. Goluch-Koniuszy ZS. Nutrition of women with hair loss problem during the period of menopause. Przeglad Menopauzalny. 2016.
7. Kantor J et al. Decreased serum ferritin is associated with alopecia in women. Journal of Investigative Dermatology. 2003.
8. Trüeb RM et al. Diffuse hair loss. Dermatologic Clinics. 2021.
9. Almohanna HM et al. The Role of Vitamins and Minerals in Hair Loss: A Review. Dermatology and Therapy. 2019.
10. Endocrine Society. Clinical Guidance on Investigational Incretin Therapies. 2024.
11. American Academy of Dermatology. Hair Loss: Diagnosis and Treatment Clinical Resources. Accessed May 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a telehealth platform connecting patients with independent licensed clinicians and U.S. state-licensed pharmacies. FormBlends does not manufacture, prescribe, or dispense medication. FormBlends does not sell, supply, or formulate retatrutide. Retatrutide is investigational and not FDA-approved as of May 2026.

Compounded Medication Notice. Compounded semaglutide and compounded tirzepatide available through FormBlends-connected 503A state-licensed compounding pharmacies are not FDA-approved drugs. They are prepared in response to individual prescriptions. Patients using these medications may experience telogen effluvium proportional to weight loss magnitude. Retatrutide is not offered as a compounded preparation through FormBlends.

Results Disclaimer. Adverse event rates cited reflect phase 2 trial averages and may not predict individual experience. Hair loss is a recognized risk of significant weight loss from any cause. Individual factors including baseline ferritin, thyroid function, protein intake, and genetic susceptibility affect risk and outcome.

Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Retatrutide is the international nonproprietary name for an Eli Lilly investigational compound. FormBlends is not affiliated with Eli Lilly, Novo Nordisk, the American Academy of Dermatology, or any cited research sponsor.